WO2024147087 - COMPOSITIONS COMPRISING COENZYME Q10 AND THEIR USE FOR TREATING EYE- AND HEART DISORDERS
National phase entry:
Publication Number
WO/2024/147087
Publication Date
11.07.2024
International Application No.
PCT/IB2024/050030
International Filing Date
02.01.2024
Title **
[English]
COMPOSITIONS COMPRISING COENZYME Q10 AND THEIR USE FOR TREATING EYE- AND HEART DISORDERS
[French]
COMPOSITIONS COMPRENANT LA COENZYME Q10 ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES OCULAIRES ET CARDIAQUES
Applicants **
BAUSCH + LOMB IRELAND LIMITED
Citywest Business Park
3013 Lake Drive
Dublin, D24, IE
Inventors
STEIN, Daniel
c/o Bausch + Lomb Ireland Limited
Citywest Business Campus, 3013 Lake Drive
Dublin, D24, IE
CORTINA, Christopher
c/o Bausch + Lomb Ireland Limited
Citywest Business Campus, 3013 Lake Drive
Dublin, D24, IE
Priority Data
63/478,306
03.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2801 | |
| EPO | Filing, Examination | 35824 | |
| Japan | Filing | 597 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 16310 |
Total: 56107 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure describes compositions comprising vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin, and coenzyme Q10, and pharmaceutically acceptable salts of any of the foregoing. The compositions are useful in methods for treating conditions associated with a loss of visual acuity including, for example, age-related macular degeneration as well as supporting heart health.[French]
La présente divulgation concerne des compositions comprenant de la vitamine C, de la vitamine E, du zinc, du cuivre, de la lutéine, de la zéaxanthine et de la coenzyme Q10, et des sels de qualité pharmaceutique de l'un quelconque des composés précédents. Ces compositions se révèlent utiles dans des méthodes de traitement de pathologies associées à une perte d'acuité visuelle comprenant, par exemple, la dégénérescence maculaire liée à l'âge, ainsi que pour améliorer la santé cardiaque.